The efficacy of adoptive TIL therapy has also been assessed in several clinical trials for solid tumors, including CRC [150,151,152,153]; however, the response rates were lower than those reported in melanoma, possibly because of the lower presence of tumor-reactive CD8+ T cells in the tumor microenvironment because the number of somatic mutations generating neoantigens was much lower in most sporadic CRCs [154]. This evidence concerns the gene CD8A and neoplasm.